Fecal Microbiota Transplantation (FMT) is an investigational treatment. The Food & Drug Administration (FDA) regulates FMT as an investigational drug. FMT may currently be used to treat recurrent C. difficile infection under an interim policy of ‘enforcement discretion’.

More research is needed to ensure that patients will continue to have access to FMT and similar microbiome-based treatments. This research will build a greater body of evidence to determine the long-term safety and efficacy profile of FMT. The FDA may use this information to approve a specific product or to inform the regulations governing the use of FMT.

How can you help? Talk to your patient about their interest in participating in clinical research or clinical trials.

Clinical trials investigating microbiome-based therapies for treating recurrent C. difficile

This publicly-available information has been compiled by OpenBiome to serve as an informational resource to clinicians and patients with C. difficile. Please contact trial sponsors for additional details.

Patients who receive FMT may be eligible to participate in the American Gastroenterological Association’s FMT National Registry. The Registry will assess short- and long-term patient outcomes associated with FMT by tracking 4,000 patients over ten years. The AGA is collaborating with OpenBiome and the American Gut Project on this study. 

Participating in clinical trials is voluntary. You have the right not to participate, or to end your participation in the clinical trial at any time. Ask questions about any information you don’t understand or find confusing. 

Trial Trial Description Eligibility Contact Information


Oral Capsule to treat
recurrent CDI
2+ CDI episodes Contact: PRISM3trial@finchtherapeutics.com
Click Here For Trial Information


Enema to treat recurrent
2+ CDI episodes Contact: nroupha@emory.edu
Click Here for Trial Information


Oral Capsule to treat
recurrent CDI
2+ CDI episodes Contact: dtilton@vedantabio.com
Click Here for Trial Information

Note: There are two additional industry-sponsored trials investigating microbiome-based therapies for treating recurrent C. difficile; they have declined to participate in this initiative. You may learn more at ClinicalTrials.gov.

Find a Clinical Trial for treating recurrent C.difficile infection

Use the map below to find the closest trial sites to you. Please contact the trial coordinators directly for more information about eligibility and enrollment.

Does OpenBiome have any stake in these clinical trials?

OpenBiome has a collaboration with one of the industry groups listed in this guide, Finch Therapeutics, which you can learn more about here: www.openbiome.org/finch-collaboration/, and is collaborating with the American Gastroenterological Association on the FMT National Registry. Learn more here.

OpenBiome is committed to providing safe access to FMT for C. difficile patients. Since current FDA guidelines consider FMT an investigational treatment, we believe the best option for long term access for patients is for industry groups to seek FDA approval for FMT or a similar microbiome-based treatment.